Genmab A/S (GNMSF) Receivables - Net (2019 - 2026)

Genmab A's (GNMSF) quarterly Receivables - Net came in at $968.0 million in Q1 2026, down 12.95% on a QoQ basis from $1.1 billion in Q4 2025.

Genmab A/S (GNMSF) Receivables - Net (2019 - 2026) Analysis & Trends

Genmab A (GNMSF) has 5 years of Receivables - Net data on file, last reported at $968.0 million in Q1 2026.

Quarterly Receivables - Net changed N/A year-over-year to $968.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $968.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.1 billion, up 19.57% from the prior year.
Receivables - Net fell to $968.0 million in Q1 2026, from $1.1 billion in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $1.1 billion in Q4 2025 to a low of $743.0 million in Q4 2023.
A 4-year average of $950.2 million and a median of $968.0 million in 2026 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2024 — Receivables - Net grew 25.17% — and 2025, when it gained 19.57%.
Tracing GNMSF's Receivables - Net over 4 years: stood at $743.0 million in 2023, then grew by 25.17% to $930.0 million in 2024, then climbed by 19.57% to $1.1 billion in 2025, then declined by 12.95% to $968.0 million in 2026.
The last three Receivables - Net figures came in at $968.0 million (Q1 2026), $1.1 billion (Q4 2025), and $998.0 million (Q2 2025), per Business Quant data.

Download Data